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Introduction. The following study focuses on the efficacy of the IORT (14.4 izoGy2.0) as part of conservative surgery with 
adjuvant EXRT (50 Gy in 25 fractions) for low risk 109 early breast cancer patients and 106 intermediate or nonlinear high 
risk patients with adjuvant chemoradiation or chemotherapy followed by the EXRT.
Material and methods. The accumulation of the rates of local recurrences (LR) and distant metastases (DM) are charac-
terized by nonlinear but two-phase curves. 
Results. During the first 5 years, 67% of all LR, and only 43% of all DM occurred, and between the 8th and 10th years the 
LR curve steeply increases by 25% and the DM by 48%. 
Conclusion. This suggest that a 5-year follow-up is too short and should be extended to 10 years. Among the analyzed 
prognostic factors, the time interval (TI) between IORT and adjuvant EXRT has occurred the major prognostic risk factor. If 
the TI is extended over 60 days (delayed EXRT), the LR and the DM risk undergoes a3–10 fold increase. Concurrent CH-EXRT 
significantly lowers local and distant failures, compared with delayed EXRT after completing CHT. Therefore, delayed EXRT 
completely ruins the expected efficacy of the IORT.
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Introduction 
Since the 1960s when Abe and Takahashi [1] presented the 
basic rationale and methods of intraoperative radiotherapy 
(IORT), this method has been widely used alone, or combined 
with external irradiation (EXRT) and/or chemotherapy (CHT) 
to improve the treatment outcomes of various malignant 
tumors, including breast cancer. The results of the IORT as 
a single therapy has been critically evaluated [2, 3]. Reitsamer 
et al. [4] noted no local recurrences of breast cancer after IORT 
BOOST combined with EXRT, but the follow-up was too short. 
Herskind et al. [5–7], presenting the radiobiological aspects 
of the IORT, has focused on the biological advantages of this 
method. Recently, Fastner et al. [18]  published a comprehen-
sive overview of the role of the IORT as the ESTRO IORT TASK 
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Force/ACROP recommendations, suggesting this method as 
a favorable standard of combined therapy for carefully selected 
locally advanced breast cancer patients. Despite the many 
studies, it is not easy to interpret the results of various IORT 
doses combined with EXRT and/or chemotherapy. The majority 
of studies concentrate on local recurrence as the major end-
-point, but incidences of distant metastases are usually ignored. 
Moreover, adjuvant therapy post conservative surgery (CBS) 
includes various methods, i.e. concurrent chemoradiation, 
chemotherapy followed by EXRT or the reverse. 
For high risk breast cancer patients, the IORT with CBS 
might not be effective enough mainly, when adjuvant EXRT 
is delayed, because among others processes, repopulation of 
the survived cancer cells accelerates, and therefore decreases 
or even thwarts the expected efficacy of the IORT. It seems 
that the longer the delay of postop. EXRT, the higher the risk 
of local recurrence. Because the prognostic importance of 
the time interval between CBS (IORT) and EXRT has not been 
evaluated yet, the present study is mainly focused on this topic. 
Material 
The retrospective clinical material consists of 215 consecutive 
breast cancer patients (T1–2N0–N+) treated in a single insti-
tution. Clinical and pathological characteristics (tab. I) were 
used to subdivide all cases into two groups, i.e. (A) – 109 cases 
with low, and (B) – 106 cases with intermediate or high risk of 
local and/or distant failure (risk factors: poorly differentiated, 
positive estrogen/progesterone, HER-2 positive, extracapsular 
nodal involvement, too narrow surgical margins, regional nodal 
involvement). There were 162 cases with pT1 (75%), and the 
remaining cases had pT2. Similarly, a 3:1 ratio concerned the 
incidence of pN0 versus pN+. In the group A dominated pT1N0 
whereas pT2N+ in the group B. A higher rate (45%) of pN+ 
was in group B, compared to a marginal rate (4%) in group A.
Methods 
Treatment characteristics 
During CBS, all cases received intraoperative radiothera-
py (IORT) performed using the INTRABEAM mobile device 
emitting low energy X-rays (20–50 kV). Spherical applicators 
were tailored to the size of the postoperative tumor bed. The 
planned dose covered 0.5–1 cm of the tissue surrounding 
the postoperative margin, and usually a single dose of 5 Gy 
was delivered. Since the RBE for X-rays of 20-50 kV is higher 
(~1.5–1.6) than that for high energy photons (~1.0), an effective 
IORT single dose was 7.5 Gy. Postoperative EXRT used 50 Gy 
in 25 fractions. To estimate the izoeffective biological dose of 
these two different schedules, a Normalized Biological Effective 
Dose (NBED) was calculated using a Linear-Quadratic formula 
with a/b value of 4.0 Gy:
NBEDTOTAL = RBE • NBEDIORT + NBEDEXT.
= 14.4 izoGy2.0 + 50 izoGy2.0 = 64.4 izoGy2.0
assuming that EXRT was delivered in the shortest possible time 
after completing the CBS.
Adjuvant therapy 
Postoperative radiotherapy (EXRT) of 50 Gy, given in 25 frac-
tions using 3D-IMRT as a sole adjuvant treatment was delivered 
to patients in group A. In group B, EXRT was combined with 
CHT as concurrent chemoradiation (with antracyclin, CTX and 
5-Fu) in 62 cases (58%), and in the remaining 42%, EXRT was 
delayed after completing the CHT. Therefore, the time interval 
(TI) between CBS (IORT) and adjuvant therapy widely differed 
between group A and B. In group A, the TI was in the range of 
10–45 days, whereas in 74% of the B cases, TI was delayed over 
90 days, and in 40% of cases it was even longer than 120 days.
Hormonotherapy (tamoxifen) was additionally admini-
stered to 75% of patients and continued up to 5 years after 
completing combined therapy.
End-points 
A ten-year follow-up was the only end-point to estimate the 
incidence of local recurrence free (LRFS) and distant meta-
stases-free (DMFS) survival. The relationships between the 
accumulated incidence of LR and DM during the follow-up and 
the sequence of adjuvant treatment, including the TI between 
CBS (IORT) and the EXRT, were counted using the Spearman 
correlation, the multivariate Cox’ regression analysis and the 
t-Student test modified by Yates. An estimate of p < 0.05 was 
accepted as a level of significance.
Results 
The actuarial 10-year local tumor control (LTC) was 94.4% 
(97.1% in gr. A and 91.6% in gr. B), and disease-free survival 
(DFS) of 84.8% (93.5% in gr. A and 74.2% in gr. B).
Incidence and kinetics of local and distant failures 
There were 12 local recurrences (LR – 5.6%) and 21 distant 
metastases (DM – 9.7%) during the 10-year follow-up. Altho-
ugh overall incidence of the LR or DM was not high, the LR 
rate in group B doubled when compared with group A; the 
DM incidence in group B was 4-times higher than in group A. 
Accumulation of the LR and the DM rates during the 10-year 
follow-up did not regularly and gradually increase, what is 
unusual attribute of these events. On the contrary, two-phase 
Table I. Clinical material characteristics






pT1 95–87% 67–63% 162–75%
pT2 14–13% 39–37% 54–25%
pN0 105–96% 56–55% 161–75%
pN+ 4–4% 48–45% 52–24%
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accumulation curves representing both types of failure were 
noted. The first phase concerns the 5-year follow-up, during 
which the accumulated rate of the LR gradually increased to 
67%, and the DM to 43% (tab. II). 
During the next two years (6th and 7th), the LR and DM 
rates slowed down, showing more or less a “plateau effect”, 
and during the 8th to 10th year the accumulated rate of the LR 
steeply increased by 25%, and the DM by 48%. It seems that 
such an irregular accumulation rate of both failures might be 
explained by the biological and prognostic inhomogeneity 
of the two groups of patients with low vs. intermediate or 
high risk, and by the different aggressiveness of combined 
treatment modalities, lower in group A, and higher in group B. 
The impact of the time interval (TI) between CBS 
(IORT) and adjuvant therapy on treatment outcomes
In 82 cases (75%) in group A, the TI ranged from 10 to 45 days, 
and in the remaining 27 cases (25%) the postoperative EXRT 
was delayed to over 60 days (for unknown reasons). On the 
contrary, in 28 cases (26%) in group B, the TI was shorter than 
60 days (all received concurrent chemoradiation). Therefore, 
the TI of 60 days was arbitrarily chosen as the “TI cut-off li-
mit”. Table III shows that the duration of the TI had significant 
(p < 0.005) impact on the incidence of the LR, which in group 
A and B did not occur if the TI was shorter than 40 days (fig.1). 
However, the kinetics of the DM differed. For the TI up to 60 
days it was low (1.2%) in group A, but in group B it was much 
higher, up to 14%. When the TI gradually extended above 
80  days, the incidence of the LR and the DM significantly 
(p < 0.001) increased, being much higher in group B than A.
Extension of the TI in group B depended on whether EXRT 
was delivered concurrently with CHT or was delayed after com-
pleting CHT. The retrospective character of the analysis does 
not explain the reason for the two different ways of treatment 
decision. The delayed EXRT after completing CHT resulted in 
a 5-fold higher incidence of the LR (p < 0.005) and more than 
doubled incidence of the DM (p < 0.001). Figure 1 suggests 
that postoperative adjuvant therapy should begin as soon as 
possible but not later than 40–50 days after completing CBS 
(IORT). Furthermore, for patients in group B (intermediate or 
high risk) optimally effective is concurrent CHT-EXRT, which 
lower the risk of both the LR and the DM (tab. IV).
Table II. Number, overall and accumulated rates of Local recurrences and distant metastases during three time intervals within 10-year follow-up
Factors Follow-up in years Significance
(p)1–5 6–7 8–10
local recurrence
number (No.) 8 1 3 <0.005
overall rate 3.7% 0.5% 1.4% –
accumulated rate 67% 75% 100% –
distant metastases
number (no.) 9 2 10 <0.0001
overall rate 4.1% 0.9% 4.7%
accumulated rate 43% 52% 100%
Table III. Incidence of local recurrences (LR) and distant metastases (d. meta) in the group A and B depending on time interval (TI) between CBS (IORT) and 
adjuvant EXRT. For TI 60 days was accepted as border time
Border  time
2.0 60 days 140
LR dist. meta LR d. meta
group A 0/82 1/82 – 1.2% 3/27 – 11% 3/27 – 11%
group B 0/28 4/28 – 14.3% 9/78 – 11.5% 13/78 – 17%




Table V. Results of multivariate Cox’ regression analysis of the LR and DM risk factors
Factors LR DM
HR (p) HR (p)
pT 1.95 0.021 2.28 0.014
pN 2.6 0.001 4.75 0.0004
number of involved regional nodes (x) 1.18x 0.32 1.36x 0.0001
time interval (TI) between IORT and EXRT 4.83 0.013 1.29 0.62
delayed time of EXRT after IORT above 60 days (n – days > 60) 1.02n 0.0008 1.02n 0.0007
concurrent CHT-EXRT 0.07• 0.0014 0.34• 0.035
EXRT delayed after completing CHT 14.28 0.001 2.94 0.035
[ x – if x = 1 then HR = 1.18, but for x = 5, HRLR = (1.18)
5 – 1 = 1.29 and HRDM = (1.36)
5 = 3.65
n – if TI increases by 20 days above 60 d limit then HR = (1.02)20 = 1.485 means an increase of LR/DM by 48.5% of that for TI £ 60 days
• – risk of LR decreases by 93% (1 – HR = 1 – 0.07 = 0.93) and DM by 66% (1 – HR = 1 – 0.34 = 0.66) compared with those for sequential EXRT after CH] 
the TI of 60 days or less. On the contrary, concurrent chemo-
radiation resulted in significant (p < 0.001) decrease of the 
LR risk by about 94% and the DM risk by 66%. The OTT of the 
EXRT was more or less the same (about 35 days) in all cases, 
therefore its prognostic power can be neglected, but the time 
interval between CBS (IORT) and the start of the postop. EXRT 
seems to be the major determinant of the LR and DM risk, 
mainly in group B, if the EXRT was considerably delayed after 
completing the CHT.
Discussion 
Since Veronesi [8] and Bartelink [9, 10] convincingly documen-
ted that early advance breast cancer patients need adjuvant 
radiotherapy after CBS, it was recognized that EXRT alone is 
not effective enough (7–15% LR), especially for intermediate 
or high risk patients (11–15%). It became obvious that co-
nventional adjuvant EXRT needs a boost dose. Intraoperative 
radiotherapy using a single dose became an interesting solu-
tion. Although the use of IORT and adjuvant EXRT in the early 
Multivariate analysis (tab. V) shows that pN is the strongest 
risk factor of the DM together with the number of involved 
regional nodes. If their number increases, i.e. from 1 to 5 posi-
tive nodes, the DM-HR (hazard ratio) becomes about 2.5-times 
higher (3.65/1.36 – see the bottom of tab. V). The highest LR 
risk factor strongly correlated with the EXRT delayed after 
completing CHT (HR = 14.28). If the TI between CBS (IORT) was 
80 days (20 days longer than the TI cut-off limit of 60 days), HR 
increases to 1.0220 = 1.485, which means an increase of the 
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Figure 1. Incidence of local recurrence (LR) and distant metastases (DM) in the group A and B depending on time interval (TI) between CBS (IORT) and 
EXRT
Table IV. 10-year failure rates depending on the sequence of postoperative 
combined therapy in the group B
Sequence of postoperative 
therapy
Failures during 10-year follow-up
LR dist. meta
concurrent cht-exrt 2/62 – 3% 6/62 – 10%
cht followed by exrt 7/44 – 16% 12/4 – 27%
significance (p) <0.005 <0.001
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stages of breast cancer with no or low risk factors raised some 
doubts, Van Dongen et al. [16] and Clark et al. [17] strongly 
recommended IORT as a boost method preceding CBS. A re-
cent comprehensive overview of the role of IORT in breast 
conserving therapy [18] provides the largest evidence of the 
high efficacy of the IORT with a single dose of 10–20 Gy, using 
electron beams. However, in the majority of the presented 
studies, the follow-up was shorter than 10 years (3–8 years). 
The IORT single dose of 14.4 izoGy2.0 used in the present study 
is within the range of electron IORT doses of 10–20 Gy, due 
to the higher RBE of 20–50 kV X-rays, compared with that of 
electrons (RBE = 1.0). It is surprising that the recent ESTRO 
IORT TASK [18] aspires to recommend IORT but it raises some 
doubts and uncertainties. Local control and overall survival 
have been the only end-points and are related on average to 
only a 5-year actuarial follow-up, and the DM incidence has 
not been considered. The present study shows that beside the 
LR, the DM risk should not be ignored. Moreover, both failures 
accumulate nonlinearly during the follow-up (tab. II), and the 
5-year follow-up is definitively too short, because about 30% of 
the LR and 55% of the DM can easily be missed, since they may 
occur later mainly between the 7th to 10th year of the follow-up.
A recent ESTRO IORT TASK overview is focused on stage I–II 
breast cancer patients but no/low and intermediate/high risk 
patients are pulled together, whereas our study suggests that 
these two groups should be analyzed separately. 
Bellon et al. [19] pointed out that sequence of CHT and 
EXRT for intermediate/high risk patients plays a very important 
role, but in the ESTRO TASK overview, the time interval (TI) be-
tween IORT and adjuvant EXRT was not accounted, for similarly 
to Vaidya et al. [20, 21] in the TARGIT-A trial. On the contrary, 
multivariate analyses in the present study indicates the TI as 
the major determinant of the LR and DM risk. Considerable 
delay of the EXRT after completing postoperative CHT leads 
to the highest risk of the LR (HR = 14.28), even in the low risk 
group, where lengthening the TI over 60 days resulted in an 
increase of the LR from 0% to 11%, and the DM from 1.2% to 
11% (tab. III). A similar trend was also noted in group B. It may 
suggest that the TI lengthened over 60 days can completely 
ruin the efficacy of the IORT considered as a boost dose, and 
therefore, the necessity of its application might be questioned. 
Conclusions 
The present study suggests that the IORT as a part of con-
servative combined therapy for early stage breast cancer 
patients can be an effective boost, but only when the time 
interval (TI) between the IORT and EXRT is as short as possible. 
For intermediate/high risk patients, concurrent chemora-
diation is highly advantageous to the CHT followed by the 
EXRT because this sequence lengthens the TI between the 
IORT and EXRT, and therefore it wastes therapeutic efficacy 
of the IORT as a boost dose. Finally, it seems that a 10-year 
follow-up should be considered as standard because in the 
shorter period (i.e. 5 years) about 40% of LR and even more 
DM can easily be missed. 
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